Prestige Consumer Healthcare (NYSE:PBH) Receives “Hold” Rating from Jefferies Financial Group

Prestige Consumer Healthcare (NYSE:PBH)‘s stock had its “hold” rating reiterated by investment analysts at Jefferies Financial Group in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $76.00 price objective on the stock, up from their previous price objective of $70.00. Jefferies Financial Group’s price target points to a potential upside of 5.10% from the stock’s previous close.

Separately, DA Davidson upped their price target on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.20.

Prestige Consumer Healthcare Stock Down 1.0 %

PBH opened at $72.32 on Tuesday. The stock has a market cap of $3.59 billion, a price-to-earnings ratio of 17.34, a price-to-earnings-growth ratio of 2.08 and a beta of 0.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.90 and a current ratio of 3.23. The firm’s fifty day moving average is $71.25 and its 200 day moving average is $69.65. Prestige Consumer Healthcare has a fifty-two week low of $56.34 and a fifty-two week high of $75.80.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.86 by $0.04. The business had revenue of $267.10 million for the quarter, compared to the consensus estimate of $260.54 million. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The business’s revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.06 earnings per share. On average, sell-side analysts forecast that Prestige Consumer Healthcare will post 4.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Large investors have recently made changes to their positions in the company. Opal Wealth Advisors LLC purchased a new position in Prestige Consumer Healthcare during the 2nd quarter valued at approximately $26,000. Principal Securities Inc. bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at approximately $29,000. Quest Partners LLC grew its holdings in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after purchasing an additional 424 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in Prestige Consumer Healthcare by 80.6% in the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new stake in Prestige Consumer Healthcare during the second quarter valued at $35,000. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.